Compare ARK Genomic Revolution ETF (ARKG) vs Avient Corporation (AVNT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Avient Corporation — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Avient Corporation trades at $35.51 (market cap $3.30B). The key difference: Avient Corporation pays a 3.05% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Avient Corporation nearer its low. Which is the better fit depends on your goals.
| ARKG | AVNT | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $43.28 |
52-Week Low | $23.09 | $27.48 |
Market Cap | — | $3.30B |
Enterprise Value | — | $4.80B |
Dividend Yield | — | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Avient Corporation (AVNT) trades at $36.03, showing modest daily gains of 0.14%. The stock exhibits bearish technical signals with moving averages and ADX indicators pointing downward, though RSI levels remain neutral. Fundamentally, the company maintains stable revenue around $3.3 billion with improving profitability, as evidenced by three consecutive quarterly earnings beats. Recent product launches in barrier technology and dielectric thermoplastics demonstrate innovation in materials solutions.
Avient presents a mixed investment case with strong analyst support (60% buy ratings) offset by technical weakness. The company's consistent earnings performance and dividend payments provide stability, while competitive pressures and market volatility remain key risks. Near-term catalyst includes Q2 2026 earnings release on August 6, 2026, where the company faces expectations of $0.89 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →
